基质金属蛋白酶9、乙酰肝素酶及组织蛋白酶L可溶芯片诊断试剂盒的制备和临床验证

Preparing Suspension Array Diagnostic Kit of Matrix Metallo Proteases 9,Heparanase and Cathepsin L and Clinical Validating

目的建立卵巢癌患者血清中基质金属蛋白酶9（matrix metallo proteases 9，MMP9）、乙酰肝素酶（heparanase，Hpa）及组织蛋白酶L（cathepsin L，CL）3种细胞基质酶的悬浮芯片检测方法并探讨它们在卵巢癌诊断中的临床价值。方法采用抗体包备荧光微球法制备MMP9、Hpa和CL悬浮芯片，并用悬浮芯片技术和酶联免疫法检测83例卵巢癌患者，50例卵巢良性肿瘤患者及55例健康妇女血清中3种酶的浓度。比较两种方法对3种酶的定量检测以及判别卵巢肿瘤良恶性和病变程度的效能。结果悬浮芯片法检测3种酶的动态范围为7～2056u／ml，变异系数范围为3．39％～6．15％，相应的酶联免疫法动态范围为20～1024u／ml，变异系数范围是6．45％～11．82％，采用悬浮芯片检测血清MMP9、Hpa和CL含量诊断卵巢肿瘤良恶性的敏感度和特异性分别为90．4％和92．0％，术前判断卵巢癌病变程度的敏感度和特异性为91．1％和92．6％。结论悬浮芯片方法检测血清蛋白的含量比酶联免疫法具有更高的敏感度和更宽的动态检测范围，它能够实现高通量、多因子分别定量的快速检测。采用悬浮芯片方法检测血清MMP9、Hpa和CL含量可用于卵巢癌的诊断和判断病变的程度。

Objective To develop a rapid, high-throughput screening method of suspension array technique to simultaneously detect matrix metallo protenases 9（MMP9）, heparanase（Hpa）, and cathepsin L（CL） in serum, and to explore their clinical diagnosis value for ovarian cancer. Methods The suspended arrays of MMP9, Hpa and CL were prepared by adopting the fluorescent microspheres coated with antibody. Suspension array technology and enzyme-linked immunosorbent assay were performed to detect serum concentrations of MMP9, Hpa and CL in 83 patients with ovarian cancer, 50 cases of benign ovarian tumor and 55 cases of healthy womerL The sensitivity of two methods was analyzed. Results The dynamic range of suspension array was 7-2 056 u/ml, coefficient of variation was 3. 390%-6. 15 %. The corresponding linear range of enzyme-linked immunosorbent assay was 20 - 1 024 u/ml, coefficient of variation range was 6. 45 %- 1 l. 82%. The sensitivity and specificity of MMP9, Hpa and CL combined detection by suspension array were 90. 4% and 92. 0% respectively in diagnosis of ovarian cancer. Similarly the sensitivity and specificity were 91.1 % ,92. 6% in diagnosis of ovarian cancer before surgery. Conclusion Suspension array of MMP9, Hpa and CL has higher sensitivity and wider dynamic range than ELISA method in detecting serum protein, and is a high-throughput, multi-factor quantitative rapid detection for ovarian cancer,